Announcements Trials
Browse Landscape

Phase

Phase 2/3 3

Status

Completed 15Unknown 5Terminated 4Not yet recruiting 3Recruiting 2Withdrawn 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Gastrointestinal 3

Conditions

Colorectal Neoplasms 17Breast Neoplasms 14Rectal Neoplasms 12Nasopharyngeal Carcinoma 8Stomach Neoplasms 5Triple Negative Breast Neoplasms 3Colonic Neoplasms 3Cholangiocarcinoma 3Carcinoma, Hepatocellular 3Biliary Tract Neoplasms 3Adenocarcinoma 3Recurrence 2Pancreatic Neoplasms 2HER2-positive Gastric Cancer 2Esophageal Squamous Cell Carcinoma 2Carcinoma, Non-Small-Cell Lung 2Spinocerebellar Degenerations 1Rectal Neoplasms Malignant 1Rectal Cancer Patients 1Preventive Effect of Quintuple Therapy on Metachronous Liver Metastases in Patients With Colorectal Cancer 1Pathologic Complete Response 1Pancreatic Cancer Resectable 1Pancreatic Cancer Non-resectable 1Neoplasm Metastasis 1Nasopharyngeal Neoplasms 1Nasopharyngeal Cancinoma (NPC) 1Mouth Neoplasms 1Metastatic Breast Cancer in the Brain 1MSI-H Colorectal Cancer 1Locally Advanced Rectal Cancer (LARC) 1

Interventions

lenvatinib 16Bevacizumab 14sintilimab 11tislelizumab 9apatinib 8regorafenib 6donafenib 6camrelizumab 5atezolizumab 4Immune Checkpoint Inhibitors 4Hepatectomy 4durvalumab 3Radiosurgery 3Capecitabine 3spartalizumab 2pembrolizumab 2cabozantinib 2anlotinib 2Specimen Handling 2Oxaliplatin 2Observation 2Magnetic Resonance Spectroscopy 2Injections 2Immunotherapy 2Folfox protocol 2Fecal Microbiota Transplantation 2Electroporation 2Blood Specimen Collection 2ursodoxicoltaurine 1tremelimumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Not yet recruiting × Carcinoma, Hepatocellular × Capecitabine × Clear all
NCT07392866 2026-02-09

A Clinical Study of SH006 Injection in Combination Therapy Versus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma

Nanjing Sanhome Pharmaceutical, Co., Ltd.

Phase 2/3 Not yet recruiting
120 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT07309419 2025-12-30

Cocktail-001

Shanghai Zhongshan Hospital

Phase 2/3 Not yet recruiting
222 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

NCT05976568 2023-08-04

A Study of QL1706 in Combination With Bevacizumab and/or Chemotherapy as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma

Qilu Pharmaceutical Co., Ltd.

Phase 2/3 Not yet recruiting
668 enrolled
Gastrointestinal

Carcinoma, Hepatocellular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡